Lactobacillus reuteri - BioGaia

Drug Profile

Lactobacillus reuteri - BioGaia

Alternative Names: Apylori Probiotic Capsules; BioGaia ProTectis; IBP 9414; Lactobacillus reuteri ATCC 55730; Lactobacillus reuteri DSM 17938; Lactobacillus reuteri Protectis; NEC therapy - BioGaia

Latest Information Update: 06 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioGaia; Infant Bacterial Therapeutics
  • Developer BioGaia
  • Class Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute enterocolitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastrointestinal disorders
  • Phase II Acute enterocolitis; Constipation; Type 2 diabetes mellitus
  • Clinical Phase Unknown Colic

Most Recent Events

  • 26 Jun 2018 BioGaia plans the phase III "The Connection Study" trial for Acute enterocolitis (Prevention, In neonates) in North America and Europe in the second half of 2018
  • 11 Dec 2017 Adverse events data from a phase II trial in Acute enterocolitis released by Infant Bacterial Therapeutics
  • 24 Nov 2017 BioGaia intends to seek marketing approval for Lactobacillus reuteri for Acute enterocolitis in USA and Europe by 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top